Hanjoon Alex Kim - Apr 4, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Chief Operating Officer
Signature
/s/ Hanjoon Alex Kim by Agnieszka Gallagher, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
Apr 4, 2024
Transactions value $
$0
Form type
4
Date filed
4/5/2024, 06:58 PM
Previous filing
Apr 6, 2023
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Options Exercise $0 +70.2K +100% $0.00 140K Apr 4, 2024 Direct
transaction LAB Common Stock Award $0 +70.7K +50.37% $0.00 211K Apr 5, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Restricted Stock Units Options Exercise $0 -70.2K -33.33% $0.00 140K Apr 4, 2024 Common Stock 70.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 11, 2023, the Reporting Person was granted a target amount of 77,185 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 70,702 RSUs as of March 31, 2024.
F2 Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023.